Cardinal Health Posts Higher Full-Year Profit on a Higher Top Line, With Operating Cash Flow Rising and Dividend Cash Outlays Falling

Bottom line

The bottom-line result for the twelve-month period covered by this filing is a profit on both an Operating Income (Loss) measure and a Net Income (Loss) Attributable to Parent measure, with Earnings Per Share, Diluted also positive. Compared with the prior-year comparative for the twelve-month period, Revenues, Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Earnings Per Share, Diluted each moved higher on the authorized year-over-year direction, with the operating result and the net result both staying in profit on a profit-to-profit basis.

- Revenues were $254,248,000,000 USD for the twelve months ended June 30, 2026, higher than the prior-year comparative for the twelve-month period figure of $222,578,000,000 USD for the twelve months ended June 30, 2025. - Operating Income (Loss) was $2,613,000,000 USD for the twelve months ended June 30, 2026, higher than the prior-year comparative for the twelve-month period figure of $2,275,000,000 USD for the twelve months ended June 30, 2025; the result stayed in profit on a profit-to-profit basis. - Net Income (Loss) Attributable to Parent was $1,714,000,000 USD for the twelve months ended June 30, 2026, higher than the prior-year comparative for the twelve-month period figure of $1,561,000,000 USD for the twelve months ended June 30, 2025; the result stayed in profit on a profit-to-profit basis. - Earnings Per Share, Diluted was $7.23 per diluted share USD/SHARES for the twelve months ended June 30, 2026, higher than the prior-year comparative for the twelve-month period figure of $6.45 per diluted share USD/SHARES for the twelve months ended June 30, 2025.

Reporting-period identity and source scope: this analysis is drawn from the filing of CARDINAL HEALTH INC, trading under CAH, with 0000721371 as the Central Index Key and 0000721371-26-000038 as the accession number, on the 10-K for period-ended-2026-06-30. The MD&A within this Form 10-K generally discusses fiscal items and year-over-year comparisons for the two twelve-month windows; fiscal items and year-over-year comparisons between fiscal years not included in this Form 10-K can be found in Management's Discussion and Analysis of Financial Condition and Results of Operations in the company's Annual Report on Form 10-K for the prior fiscal year. The source material also flags that forward-looking statements addressing expectations, prospects, estimates, and other matters that are dependent upon future events or developments appear throughout the filing, including in MD&A and Risk Factors, and that such statements are subject to risks and uncertainties that could cause actual results to differ materially. Non-GAAP financial measures are used in the filing and are reconciled to their most directly comparable GAAP financial measures in the "Explanation and Reconciliation of Non-GAAP Financial Measures" section following MD&A.

The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

This filing's identity was confirmed through 0000721371-26-000038, the 10-K covering period-ended-2026-06-30 for CARDINAL HEALTH INC under CIK 0000721371 with ticker CAH; readers can verify the direction of the year-over-year moves with Higher Bottom-Line Profit on a Softer Top Line for Both Windows of the Filing Period before acting on these reported numbers.

Financial performance

- Reported full-year results for CARDINAL HEALTH INC on the 10-K covering the twelve months ended June 30, 2026 show Revenues of $254,248,000,000, up from $222,578,000,000 in the twelve months ended June 30, 2025. 45 per diluted share. Each of these year-over-year comparisons is a profit-to-profit transition with an authorized increase, so all four lines moved higher and the company stayed profitable on the bottom line in both windows.

- The company reports through two reportable segments — Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution — with remaining activities in Other (Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics). Management's narrative attributes the revenue increase primarily to branded and specialty pharmaceutical sales growth from existing and new customers, and attributes the operating earnings increase to the same pharmaceutical mix, the generics program, the acquisitions of MSO platforms and ADS, and growth from existing customers in GMPD.

- Management also identifies specific offsets to the GAAP operating earnings increase: a pre-tax goodwill impairment charge in the Pharma segment tied to the Navista & Integrated Oncology Network reporting unit, higher cash and share-based compensation costs linked to the timing of acquisitions within The Specialty Alliance, and a prior-year benefit from net recoveries in class action antitrust litigation that did not repeat. Further background on the goodwill impairment is provided in the cited note referenced as Note 4 of the Notes to the Consolidated Financial Statements.

- Reconciliation items shown net of tax include an "impairments and (gain)/loss on disposals of assets, net" line, which for the period captured the Navista & ION goodwill impairment; management states this produced an adverse impact on GAAP diluted EPS after the tax benefit and the noncontrolling interest share. Management also calls out favorable changes in discrete tax items as a partial lift to EPS, partially offset by increased interest expense and the impairment of the equity interest in Outcomes. - The MD&A presents a parallel non-GAAP presentation, but the filing evidence does not provide a separate figure for non-GAAP operating earnings, non-GAAP diluted EPS, or any specific revenue or earnings dollar amount beyond the GAAP lines above; any direction stated in the filing for those non-GAAP lines is described in narrative terms rather than as a cataloged fact.

- No quarterly window is provided in the catalog, so a sequential quarter-over-quarter comparison is not available here. No forward guidance figures, target ranges, or outlook metrics are present in the quoted evidence for this section, and the filing evidence contains no peer or industry comparison, so relative performance against other distributors or healthcare companies cannot be drawn from this filing. The filing evidence does not attribute this change to any single cause.

Operating drivers and segments

- CARDINAL HEALTH INC reports financial results in two reportable segments — Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD) — with remaining operations aggregated in Other, which comprises Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. - Operating Income (Loss) was $2,613,000,000 for the twelve months ended June 30, 2026, compared with $2,275,000,000 for the twelve months ended June 30, 2025. - Revenues were $254,248,000,000 for the twelve months ended June 30, 2026, compared with $222,578,000,000 for the twelve months ended June 30, 2025. - Both Operating Income and Revenues are authorized to be reported as higher on the current twelve-month window than on the prior-year window, with each moving from a profit to a profit. - The segment-by-segment composition is described in narrative form only: no segment-level revenue or profit figure, margin ratio, or year-over-year delta is present in the catalog for this section, so any quantitative split between Pharma, GMPD, and Other cannot be asserted here.

- Management attributes the increase in GAAP operating earnings to four named drivers: a larger contribution from branded and specialty pharmaceuticals and better generics-program performance within Pharma, the impact of acquisitions of MSO platforms and ADS, and growth from existing GMPD customers. - Management then lists three explicit offsets to that increase: a pre-tax goodwill impairment charge related to the Navista & Integrated Oncology Network (ION) reporting unit inside the Pharma segment, higher cash and share-based compensation tied to the timing of acquisitions within The Specialty Alliance, and net recoveries in class action antitrust litigation recorded in the prior fiscal year. - Management separately reports that Non-GAAP operating earnings increased, citing the same Pharma-side drivers and the ADS and MSO-platform acquisitions, and points to the GAAP-to-Non-GAAP reconciliations in the cited note for quantification of tax effects. - The pharmaceuticals-with-glucagon-like profile narrative states that the CARDINAL HEALTH INC saw increased demand for the cited medications during the period, which lifted Pharma and consolidated revenue but did not meaningfully contribute to segment profit, marking a qualitative divergence between top-line benefit and bottom-line benefit on that item. - Generics-program commentary names the moving parts: generic launches, customer volumes, pricing changes, the Red Oak Sourcing venture with CVS Health, and generic contract manufacturing and sourcing costs.

Counter-evidence and unknowns: - The filing evidence contains no peer, competitor, or industry benchmark for either segment, so any read on margin gap versus peers cannot be made here. The filing evidence contains no peer or industry comparison. - No segment-level operating-income figure, segment revenue figure, or segment margin is provided in the catalog for either window; only consolidated totals are available, so a segment-by-segment attribution of the change in operating income cannot be reconstructed from this section's evidence. The filing evidence does not attribute this change to any single cause. - The acquisition-related compensation step-up, the antitrust recovery base effect, and the goodwill impairment are described qualitatively but not quantified in this section's evidence, so their net contribution to the operating-income change cannot be sized here. The filing evidence does not attribute this change to any single cause. - The reader-facing question of whether GMPD growth was volume-led or price-led is not answered by the evidence available to this section. The filing evidence does not attribute this change to any single cause. - The discussion of Phase 1 and Phase 2 phases appears in source notes but no phase-specific figure is available to cite here; similarly, cross-references to Note 4, Note 6, Note 8, and Note 13 exist as pointers but no quantified reconciliation is supplied within this section's evidence.

Independent read versus management claims: - Management's qualitative narrative is internally consistent with the authorized direction of the consolidated operating-income and revenue moves, but the lack of segment-level figures in the catalog means the analyst cannot independently verify how much of the consolidated lift came from Pharma versus GMPD versus Other. The filing evidence does not attribute this change to any single cause. - The pharmaceuticals-with-glucagon-like profile item is a clean case where management itself flags a top-line–bottom-line divergence on a specific driver, which is corroborated here only at the qualitative level. - Readers who want to pressure-test the segment story against a peer set can frame the comparison with Higher Bottom-Line Profit on a Softer Top Line for Both Windows of the Filing Period as a structural reference, but the filing evidence for CARDINAL HEALTH INC itself does not supply the underlying peer numbers.

Cash flow and capital

Reported facts The period-ended-2026-06-30 10-K filed under accession 0000721371-26-000038 by CARDINAL HEALTH INC (CAH, CIK 0000721371) presents the consolidated cash-flow statement in three sections for the twelve months ended June 30, 2026 alongside the twelve months ended June 30, 2025. Net Cash Provided by (Used in) Operating Activities was $2,397,000,000 in the prior year and $5,174,000,000 in the current year. Net Cash Provided by (Used in) Investing Activities was -$5,593,000,000 in the prior year and -$2,584,000,000 in the current year. Net Cash Provided by (Used in) Financing Activities was $1,940,000,000 in the prior year and -$1,602,000,000 in the current year. Within financing activity, Payments for Repurchase of Common Stock moved from $765,000,000 to $1,358,000,000, and Payments of Ordinary Dividends, Common Stock moved from $494,000,000 to $491,000,000. Within investing activity, Payments to Acquire Property, Plant, and Equipment moved from $547,000,000 to $649,000,000. On the balance sheet as of the balance sheet date of June 30, 2026, Accounts Payable, Current was $38,283,000,000 and Cash and Cash Equivalents, at Carrying Value was $4,856,000,000.

Management explanations Cardinal Health's MD&A and risk-factor narrative frames the tariff environment, the IEEPA refund mechanism administered by U.S. Customs and Border Protection through Phase 1 and Phase 2, and a presidential proclamation earlier in the year on imports of branded pharmaceutical products and associated ingredients. Management states the net operating earnings impact of IEEPA tariff timing and refunds was immaterial for the fiscal year, while ongoing tariff costs on sourced, manufactured, and distributed products remain only partly offset by cost optimization initiatives and customer price increases in the GMPD segment. Further operating context is offered around physician-practice support, MSO platform acquisitions, government price-cap initiatives affecting branded revenue, and the Red Oak Sourcing venture with CVS Health, with cross-references to Note 4, Note 6, Note 8, and Note 13 for related disclosures.

Analyst inference The directional pattern shown here is higher operating cash inflow than the prior period, an investing outflow at a lower level than the prior period, and a swing of financing activity to a use of cash. Capital expenditure is reported at a higher level than the prior period, share repurchases are higher than the prior period, and ordinary dividend payments are lower than the prior period. The two balance-sheet lines reported as of the balance sheet date of June 30, 2026 offer an immediate-liquidity read on cash on hand relative to current accounts payable; a year-over-year change in that ratio is not separately re-quantified here.

Counter-evidence The filing does not present a segment-level free cash flow reconciliation, does not break investing outflow into capex versus other categories, and does not provide a maturity schedule of debt repaid during the year. The broader profit and revenue trajectory is treated in other sections of this analysis.

Unknowns The filing evidence does not attribute this change to any single cause..

Peer and historical context

The historical comparison rests entirely on what 10-K period-ended-2026-06-30 filed by CARDINAL HEALTH INC (ticker CAH, CIK 0000721371, accession 0000721371-26-000038) discloses for the twelve-month period the twelve months ended June 30, 2026 alongside its prior-year comparative window the twelve months ended June 30, 2025. On a like-for-like twelve-month basis, Revenues moved higher relative to the prior twelve-month period, with the current figure of $254,248,000,000 USD compared against $222,578,000,000 USD, as authorized by the period-over-period direction recorded for the top line. Operating Income (Loss) likewise improved year over year on a profit-to-profit basis, lifting from $2,275,000,000 USD to $2,613,000,000 USD. Net Income (Loss) Attributable to Parent followed the same profit-to-profit path, rising from $1,561,000,000 USD to $1,714,000,000 USD. Net Cash Provided by (Used in) Operating Activities, which the filing reports under the same twelve-month framing, climbed from $2,397,000,000 USD to $5,174,000,000 USD on a positive-to-positive basis. Earnings Per Share, Diluted moved from a profit in the prior year to a higher profit in the current year. Taken together, the four profitability and cash-generation gauges all register higher readings in the twelve months ended June 30, 2026 than in the twelve months ended June 30, 2025.

The narrative around those movements, however, does not separate the company from peers. The filing evidence contains no peer or industry comparison. The filing does not name any comparable distributor, present industry benchmarks, or include peer revenue, margin, or capital-return figures, so no cross-company comparison can be drawn from this evidence.

Segment context supplied in management's discussion does provide a partial historical lens even though peer data is absent. The Pharma segment's twelve-month revenue rose relative to the prior year on management's stated drivers of branded and specialty pharmaceutical sales growth. The GMPD segment revenue was described as roughly flat, reflecting Cardinal Health brand growth offset by lower distribution volumes and an expected IEEPA tariff refund repayment to customers. The Other segment revenue grew relative to the prior year on contributions from at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics. Gross margin expanded relative to the prior year, with the gross margin rate higher in basis-point terms because of the cited acquisitions, partially offset by unfavorable product mix within Pharma. See Note 13 of the "Notes to Consolidated Financial Statements" for additional information on segment profit. The filing evidence does not attribute this change to any single cause.

Capital-allocation history is partly visible through authorized comparisons. Payments for Repurchase of Common Stock rose year over year on a positive-to-positive basis, Payments to Acquire Property, Plant, and Equipment rose on a positive-to-positive basis, while Payments of Ordinary Dividends, Common Stock declined on a positive-to-positive basis, indicating a continued but reduced ordinary-dividend cash outlay. Net Cash Provided by (Used in) Investing Activities became less negative and Net Cash Provided by (Used in) Financing Activities flipped from positive to negative, consistent with higher share repurchases and a lower dividend outflow. None of these patterns are mapped against any peer benchmark.

For readers who want a sense of how other reporting entities in the finance coverage have framed similar year-over-year comparisons, Higher Bottom-Line Profit on a Softer Top Line for Both Windows of the Filing Period offers a parallel structure, though it covers a different issuer and should not be read as a benchmark for CARDINAL HEALTH INC.

Scenario analysis

In a continuation case for CARDINAL HEALTH INC (CAH), the path-of-least-resistance scenario treats the headline franchise as a steady-state distribution and specialty pharmacy franchise rather than an inflection story. Revenues for the twelve months ended June 30, 2026 are higher than Revenues for the twelve months ended June 30, 2025, and Net Income (Loss) Attributable to Parent moves from the prior-year profit to a higher profit in the current twelve-month period, consistent with the authorized direction and the profit-to-profit transition. Management describes the GMPD segment as "relatively flat" on the top line, with Cardinal Health brand growth offsetting lower distribution volumes and the expected IEEPA tariff refund repayment to customers. Gross margin rate expanded, attributed by management to the acquisition of MSO platforms and partially offset by mix shifts toward branded distribution. Pharma segment profit is cited as higher on stronger branded and specialty contribution, the generics program, and the MSO platforms deal. GMPD segment profit is higher on growth from existing customers, while the Other segment profit is higher on at-Home Solutions (including ADS), OptiFreight Logistics, and Nuclear and Precision Health Solutions. The IEEPA tariff refund and the gross-margin-accretive acquisitions already embedded in the period support the assumption that this profile persists into the next twelve-month window. Interest expense, net, was higher on additional debt for recent acquisitions (see the cited note Note 6), so a continuation case carries that financing drag into the next period. The filing evidence does not attribute this change to any single cause.

The upside scenario layers three positive developments on top of the base case: branded and specialty pharmaceutical contribution compounds faster than the period's mix shift suggests; the MSO platforms and ADS acquisitions integrate ahead of plan and keep lifting blended gross margin rate, consistent with management's framing of these deals as the principal gross-margin tailwind; and tariff outcomes remain favorable because the IEEPA refund benefit recognized in the current period continues to neutralize tariff costs, which management described as "not significant." In that world, the Other segment compounds on at-Home Solutions and Nuclear and Precision Health Solutions, while GMPD returns to organic growth as the IEEPA repayment rolls off. The filing evidence does not attribute this change to any single cause. Net Income (Loss) Attributable to Parent would then extend the profit-to-profit sequence at a pace faster than the base path, and Operating Income (Loss) would track higher against the prior period, again within the authorized direction. A reader modeling this scenario can compare the directional frame against Higher Bottom-Line Profit on a Softer Top Line for Both Windows of the Filing Period, which captures a similar "bottom line up, top line roughly steady" profile. The filing evidence does not attribute this change to any single cause.

The downside scenario reverts the franchise to its softer readings. GMPD stays "relatively flat" because the IEEPA refund repayment to customers reappears or persists and offsets Cardinal Health brand growth, while branded distribution mix keeps diluting consolidated gross margin rate. Management already flagged the unfavorable product-mix shift in the Pharma segment as the partial offset to the MSO-driven gross-margin lift, so a return of that mix headwind would compress margin even if revenue holds. The Other segment stalls if at-Home Solutions (including the ADS acquisition), OptiFreight Logistics, and Nuclear and Precision Health Solutions give back part of their gains. On the cost side, higher Interest expense, net, from acquisition financing (see the cited note Note 6) compresses pre-tax earnings, and any repeat of restructuring and employee severance linked to GMPD manufacturing rationalization (discussed near the cited note Note 8 for the related goodwill impairment in the Navista & ION reporting unit) would weigh on consolidated operating earnings. Effective tax rates for both the current and prior fiscal years were described by management as primarily impacted by discrete tax items, including a benefit tied to the Navista & ION goodwill impairment, so a reversal of those one-time benefits would also compress after-tax results. Revenues remain higher year over year in the downside, but Net Income (Loss) Attributable to Parent settles back toward the prior-year profit rather than extending the increase, with Operating Income (Loss) doing the same within its authorized direction.

Across all three scenarios, the period's authorized signals hold: Revenues higher year over year, Net Income (Loss) Attributable to Parent higher on a profit-to-profit transition, Operating Income (Loss) higher on a profit-to-profit transition, Operating cash flow higher on a positive-to-positive transition, Investing cash outflow higher year over year, Financing cash flow moving from positive to negative with an authorized decrease, Payments to Acquire Property, Plant, and Equipment higher, Payments for Repurchase of Common Stock higher, and Payments of Ordinary Dividends, Common Stock lower. Earnings Per Share, Diluted moves higher within the profit-to-profit transition. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

The reporting package covers the twelve-month period and the prior-year comparative for the twelve-month period, and the four high-confidence facts available to this section are full-year revenue and net income for both windows. Revenues for the twelve-month period were higher than the prior-year comparative for the twelve-month period, and Net Income (Loss) Attributable to Parent for the twelve-month period was higher than the prior-year comparative for the twelve-month period. Both windows remained profitable on the bottom line, so the transition is profit to profit on a like-for-like basis. The filing does not include peer or industry context, so any read-across to sector multiples or distribution peers is not possible from the filing evidence; readers looking for a framing device for return on incremental invested capital may still find a general-purpose tool such as the ROI Calculator useful as a sanity check on their own assumptions.

Revenues for the twelve-month period were higher than the prior-year comparative for the twelve-month period, and both periods were positive. - Net Income (Loss) Attributable to Parent for the twelve-month period was higher than the prior-year comparative for the twelve-month period, and both periods were profits. - Operating Income for the twelve-month period was higher than the prior-year comparative for the twelve-month period, with the transition profit to profit. - Earnings Per Share, Diluted for the twelve-month period was higher than the prior-year comparative for the twelve-month period, with the transition profit to profit. - Net Cash Provided by Operating Activities for the twelve-month period was higher than the prior-year comparative for the twelve-month period, and both periods were positive. - Payments to Acquire Property, Plant, and Equipment for the twelve-month period were higher than the prior-year comparative for the twelve-month period. - Payments for Repurchase of Common Stock for the twelve-month period were higher than the prior-year comparative for the twelve-month period. - Payments of Ordinary Dividends, Common Stock for the twelve-month period were lower than the prior-year comparative for the twelve-month period, and both periods were positive.

Management described fiscal-year interest expense, net as higher than the prior year, citing additional debt financing tied to recent acquisitions, with detail carried in the cited note for borrowings. - Management disclosed a goodwill impairment charge in the Pharma segment tied to the Navista & ION reporting unit, with supporting detail in the cited note on goodwill. - Management noted net recoveries in class-action lawsuits in which it participated as a class member or plaintiff. - Management described fiscal-year operating cash flow as supported by normal vendor-payment timing, with explicit cash deployed for the Solaris Health acquisition, share repurchases, capital expenditures, debt repayment, and dividends, alongside a new long-term debt issuance. - Management stated that the prior-year operating cash flow benefited from unwinding negative net working capital tied to the OptumRx contracts and from onboarding new customers. - Management flagged ongoing exposure to tax audits through the current fiscal year, noting that new challenges could affect the effective rate.

Capital return in the form of share repurchases expanded year over year while ordinary dividends contracted, suggesting a shift in the mix of cash returned to shareholders that is consistent with a more debt-financed acquisition period. - The combination of higher interest expense, higher goodwill impairment, and higher acquisition-related cash deployment indicates that inorganic growth and balance-sheet activity were material to fiscal-year results alongside the higher operating profit.

COUNTER-EVIDENCE AND The goodwill impairment charge in the Pharma segment and the litigation recoveries both fall outside the headline revenue and net income lines, so headline profitability can overstate or understate underlying segment quality in any given quarter. - The cited notes on goodwill, borrowings, commitments and contingencies, and the segment phase language, including the initial liquefaction phase references, are pointed to by reference rather than reproduced here, so the machine-audited detail behind those disclosures is not in this section. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

METRICS TO WATCH NEXT PERIOD - Whether the higher twelve-month revenue trend continues, supported by the reported figure for the twelve-month period and the prior-year comparative for the twelve-month period. - Whether Net Income (Loss) Attributable to Parent continues to grow, supported by the reported figure for the twelve-month period and the prior-year comparative for the twelve-month period. - The trajectory of Net Cash Provided by Operating Activities, which was higher than the prior year on a positive base, against the backdrop of higher capital expenditures and higher share repurchase payments. - Interest expense, net, which management explicitly tied to acquisition financing, and the effective tax rate, which management tied to discrete items including the goodwill impairment. - Updates on the goodwill position of the Navista & ION reporting unit within the Pharma segment and on the class-action recoveries, both of which can move the bottom line without a change in operating activity.